Skip to main content

Table 2 HRU in Patients with VHL-CNS-Hb or VHL-pNET

From: Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States

 

Tumor-Related Incidence Rates

(events/100 person-years)2,3

All-Cause Adjusted Incidence Rates

(events/person-year)

All-Cause HRU IRR

Healthcare Resource Utilization

Cases

Cases

Controls

Unadjusted Model

 

Adjusted Model

 

IRR (95% CI)

IRR (95% CI)

VHL-CNS-Hb (220 cases, 1,100 controls)

       

Number of visits

       

Inpatient admissions

18.7

1.1

0.2

5.3 (3.8, 7.5)

***

4.7 (3.3, 6.7)

***

Inpatient days

175.2

9.3

0.9

10.0 (5.9, 16.9)

***

11.5 (6.3, 21.2)

***

Outpatient visits

64.3

17.8

8.9

2.0 (1.8, 2.2)

***

1.6 (1.4, 1.8)

***

ED visits

4.8

1.7

0.7

2.4 (1.6, 3.6)

***

2.0 (1.3, 3.0)

**

Other medical visits1

7.2

3.2

1.2

2.8 (1.8, 4.1)

***

2.7 (1.8, 4.2)

***

VHL-pNET (20 cases, 100 controls)

       

Number of visits

       

Inpatient admissions

37.4

2.1

0.2

10.2 (4.4, 23.7)

***

10.8 (5.3, 22.1)

***

Inpatient days

355.5

15.4

0.4

39.5 (13.2, 117.8)

***

29.6 (8.2, 106.4)

***

Outpatient visits

203.5

24.4

7.9

3.1 (2.5, 3.9)

***

1.8 (1.2, 2.7)

**

ED visits

2.3

0.9

0.9

1.0 (0.4, 2.6)

 

0.9 (0.3, 2.6)

 

Other medical visits1

2.3

2.0

0.7

3.0 (1.6, 5.6)

***

2.7 (1.3, 5.6)

**

  1. Abbreviations: CI: confidence interval; CNS: central nervous system; ED: emergency department; Hb: hemangioblastoma; HRU: healthcare resource utilization; IRR: incidence rate ratio; pNET: pancreatic neuroendocrine tumor; VHL: von Hippel-Lindau.
  2. Notes:
  3. * denotes P-values < 0.05; ** denotes P-values < 0.01; *** denotes P-values < 0.001
  4. 1. “Other” medical visits include all those not captured by inpatient, ED, or outpatient visits. These claims may reflect home health aids or physician visits among other types of ancillary medical claims
  5. 2. A claim was defined as “tumor-related” if it also had a corresponding diagnosis associated with it. See Jonasch et al. for the list of codes used for each tumor type [7]
  6. 3. The reported incidence rates for tumor-related HRU represent the estimated rates of each HRU category in 100 person-years due to the variable nature of patients’ follow-up lengths after index date
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172